Pharmacokinetics and chemotherapeutic efficacy of adriamycin encapsulated in immunoliposomes against avian myeloblastosis virus infection.
Immunoliposomes were prepared using rabbit anti-AMV gp80 IgG for the targeted chemotherapy of avian myeloblastosis virus infection. Adriamycin was encapsulated into immunoliposomes and used for in vivo studies. Comparative pharmacokinetics of free drug, drug encapsulated in free liposomes and of drug encapsulated in immunoliposomes in the virus-infected cells revealed that (i) the drug encapsulated in liposomes was cleared from the plasma slowly, and (ii) the drug encapsulated in immunoliposomes accumulated in the target tissue, the bone marrow, 5- and 8.5-fold more than the drug encapsulated in free liposomes and free drug, respectively. The drug encapsulated in immunoliposomes inactivated the virus and exhibited more chemotherapeutic efficacy as compared to controls when injected up to 24 h post-infection. However, when injected 48 h post-infection the drug encapsulated in immunoliposomes did not offer any protection against the virus infection. There is no detectable antibody response against immunoliposomes in the infected animals.
Dhananjaya
K V
KV
Tumour Biology Laboratory, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.
Antony
A
A
D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D001353:Avian Leukosis / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D009189:Avian Myeloblastosis Virus / Q000187:drug effects; D002645:Chickens; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007167:Immunotherapy; D008081:Liposomes / Q000008:administration & dosage
D000914:Antibodies, Viral; D008081:Liposomes; D004317:Doxorubicin